Media headlines about Vical (NASDAQ:VICL) have trended somewhat negative on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vical earned a daily sentiment score of -0.04 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.4497533909656 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Vical stock remained flat at $$1.55 during midday trading on Friday. 110,445 shares of the company’s stock traded hands, compared to its average volume of 193,965. The company has a market capitalization of $33.81, a P/E ratio of -1.50 and a beta of 1.33. Vical has a 12 month low of $1.32 and a 12 month high of $3.70.
Vical (NASDAQ:VICL) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.10). Vical had a negative net margin of 93.78% and a negative return on equity of 28.22%. The company had revenue of $3.95 million for the quarter, compared to the consensus estimate of $4.60 million. research analysts forecast that Vical will post -0.56 EPS for the current year.
In other Vical news, major shareholder Armistice Capital Master Fund acquired 100,000 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were acquired at an average price of $1.43 per share, for a total transaction of $143,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 5.98% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Vical (VICL) Earns Media Impact Rating of -0.04” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3300244/vical-vicl-earns-media-impact-rating-of-0-04.html.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.